In hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) breast cancer CDK4/6 inhibitors and mammalian target of rapamycin (mTOR) inhibitors are the most widely used targeted therapies, adding significant benefit to baseline endocrine therapy [4, 5]. This evidence concerns the gene CDK4 and breast carcinoma.